We will also focus on how SHP-1, SHP-2, and SHIP are involved in hematopoietic malignant diseases, particularly in AML, and the current development of leukemic therapy involving manipulation of their expression. The gene discussed is PTPN11; the disease is acute myeloid leukemia.